Author
Listed:
- Giacomo Oliveira
(Dana-Farber Cancer Institute
Harvard Medical School)
- Kari Stromhaug
(Dana-Farber Cancer Institute)
- Susan Klaeger
(Broad Institute of MIT and Harvard)
- Tomasz Kula
(TScan Therapeutics
Harvard University)
- Dennie T. Frederick
(Massachusetts General Hospital)
- Phuong M. Le
(Dana-Farber Cancer Institute)
- Juliet Forman
(Dana-Farber Cancer Institute)
- Teddy Huang
(Dana-Farber Cancer Institute)
- Shuqiang Li
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute)
- Wandi Zhang
(Dana-Farber Cancer Institute)
- Qikai Xu
(TScan Therapeutics)
- Nicoletta Cieri
(Dana-Farber Cancer Institute)
- Karl R. Clauser
(Broad Institute of MIT and Harvard)
- Sachet A. Shukla
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute)
- Donna Neuberg
(Dana-Farber Cancer Institute)
- Sune Justesen
(Immunitrack)
- Gavin MacBeath
(TScan Therapeutics)
- Steven A. Carr
(Broad Institute of MIT and Harvard)
- Edward F. Fritsch
(Dana-Farber Cancer Institute
Broad Institute of MIT and Harvard)
- Nir Hacohen
(Harvard Medical School
Broad Institute of MIT and Harvard
Massachusetts General Hospital)
- Moshe Sade-Feldman
(Broad Institute of MIT and Harvard
Massachusetts General Hospital)
- Kenneth J. Livak
(Dana-Farber Cancer Institute
Dana-Farber Cancer Institute)
- Genevieve M. Boland
(Harvard Medical School
Broad Institute of MIT and Harvard
Massachusetts General Hospital)
- Patrick A. Ott
(Dana-Farber Cancer Institute
Harvard Medical School
Broad Institute of MIT and Harvard
Brigham and Women’s Hospital)
- Derin B. Keskin
(Dana-Farber Cancer Institute
Dana-Farber Cancer Institute)
- Catherine J. Wu
(Dana-Farber Cancer Institute
Harvard Medical School
Broad Institute of MIT and Harvard
Brigham and Women’s Hospital)
Abstract
Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central to antitumour immune responses1–3; however, the relationship between phenotypic characteristics and TCR properties is not well elucidated. Here we show, by linking the antigenic specificity of TCRs and the cellular phenotype of melanoma-infiltrating lymphocytes at single-cell resolution, that tumour specificity shapes the expression state of intratumoural CD8+ T cells. Non-tumour-reactive T cells were enriched for viral specificities and exhibited a non-exhausted memory phenotype, whereas melanoma-reactive lymphocytes predominantly displayed an exhausted state that encompassed diverse levels of differentiation but rarely acquired memory properties. These exhausted phenotypes were observed both among clonotypes specific for public overexpressed melanoma antigens (shared across different tumours) or personal neoantigens (specific for each tumour). The recognition of such tumour antigens was provided by TCRs with avidities inversely related to the abundance of cognate targets in melanoma cells and proportional to the binding affinity of peptide–human leukocyte antigen (HLA) complexes. The persistence of TCR clonotypes in peripheral blood was negatively affected by the level of intratumoural exhaustion, and increased in patients with a poor response to immune checkpoint blockade, consistent with chronic stimulation mediated by residual tumour antigens. By revealing how the quality and quantity of tumour antigens drive the features of T cell responses within the tumour microenvironment, we gain insights into the properties of the anti-melanoma TCR repertoire.
Suggested Citation
Giacomo Oliveira & Kari Stromhaug & Susan Klaeger & Tomasz Kula & Dennie T. Frederick & Phuong M. Le & Juliet Forman & Teddy Huang & Shuqiang Li & Wandi Zhang & Qikai Xu & Nicoletta Cieri & Karl R. Cl, 2021.
"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma,"
Nature, Nature, vol. 596(7870), pages 119-125, August.
Handle:
RePEc:nat:nature:v:596:y:2021:i:7870:d:10.1038_s41586-021-03704-y
DOI: 10.1038/s41586-021-03704-y
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:596:y:2021:i:7870:d:10.1038_s41586-021-03704-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.